Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial.
Lancet Reg Health Eur
; 31: 100672, 2023 Aug.
Article
in En
| MEDLINE
| ID: mdl-37415648
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Aspects:
Patient_preference
Language:
En
Journal:
Lancet Reg Health Eur
Year:
2023
Document type:
Article
Affiliation country:
Francia
Country of publication:
Reino Unido